Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.
about
Minimal Residual Disease Assessment in the Context of Multiple Myeloma TreatmentEuropean perspective on multiple myeloma treatment strategies in 2014National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report.Older patients with myeloma derive similar benefit from autologous transplantation.How we manage autologous stem cell transplantation for patients with multiple myelomaDisparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myelomaTrends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era.Acute graft-versus-host disease and bronchiolitis obliterans after autologous stem cell transplantation in a patient with multiple myeloma.The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma.Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and AmyloidosisCost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare DatabaseBusulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.Controversies in multiple myeloma: to transplant or not?Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma.Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma.The role of tandem stem cell transplantation for multiple myeloma patients.Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.Racial disparities in treatment use for multiple myeloma.Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States.Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis.Observational study of multiple myeloma in Latin America.Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents.Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.Autologous stem cell transplantation in multiple myeloma is not dead but alive and well.Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.
P2860
Q26768653-8B1104AF-2329-4790-85A8-10CD34ADA7EFQ27005966-BB84BFA9-7713-4C83-8415-E1C328A50160Q30245682-9484F6C7-8128-46DF-A14A-BC24EDADA197Q30370038-796C726A-91FA-4661-9193-C148BDBFCD78Q34019581-2750782F-7EE6-4251-9078-15B8D8C8CA9FQ35180533-3E0E9269-8C79-40D7-B944-C8CB90C3675BQ35410550-3758D65F-A7AE-4587-8E59-E05AC22CD3B4Q35439366-8AE99D3E-6564-4650-BDBB-E3BA7653FF08Q35841771-CDC029D8-D2E8-44AC-A794-84874A41A1D8Q36009600-2FD3B97E-3300-4D56-B923-ED8FCA6AE04CQ36473988-FA0B1874-C32B-4C91-BD80-9088EBF1EEFBQ37066097-EDBC6A7C-6243-43AB-9530-020F00E7BEEDQ37359565-A89BD514-70DF-41D6-AC3E-CBA01A62C660Q38242006-EC29E022-7A30-451B-A26C-B46D83616165Q38554884-C903AF2B-0766-48F9-B0CF-BD170F8799D3Q38555091-FAB12289-DCFC-49DD-83F9-9905F9BB7350Q38677358-B7495516-CB94-4093-AB5A-FEDDAB0E2D2DQ38797546-680028B7-2E86-4C5C-9FB4-E77261F1ED80Q38803906-25636B3C-1DB8-41D1-A65A-09E82E3E5404Q39022279-257362EF-6B34-4C9D-A7DA-7AA5ADBAE42CQ39466768-D920A115-E526-42B0-973F-D9D7676C3A2EQ40324587-ABC9BC1B-DC37-416B-982F-D688869F3721Q40488479-0DB0F67E-1197-4C21-89A2-F75D57B2F7CFQ41694417-395C6E37-8406-47A6-89FD-D7004A688A1DQ44647017-BABFBEF5-DB92-4CB7-8F4B-C4A266CCB3A3Q47562378-BFA62A8A-5365-4215-87A9-671CCD251646Q48058540-2DC788B6-2310-4B18-8DFE-E87D6E1151B4Q50020987-F11049A0-20A1-4295-84CC-9B53669E4D88
P2860
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Trends in utilization and outc ...... therapy for multiple myeloma.
@ast
Trends in utilization and outc ...... therapy for multiple myeloma.
@en
type
label
Trends in utilization and outc ...... therapy for multiple myeloma.
@ast
Trends in utilization and outc ...... therapy for multiple myeloma.
@en
prefLabel
Trends in utilization and outc ...... therapy for multiple myeloma.
@ast
Trends in utilization and outc ...... therapy for multiple myeloma.
@en
P2093
P2860
P50
P1476
Trends in utilization and outc ...... therapy for multiple myeloma.
@en
P2093
Amrita Krishnan
Baldeep Wirk
Bipin N Savani
Cesar Freytes
David Vesole
Edmund K Waller
Harry Schouten
Kenneth Meehan
Luciano J Costa
Manish Sharma
P2860
P304
P356
10.1016/J.BBMT.2013.08.002
P577
2013-08-11T00:00:00Z